Barclays
XPH icon

Barclays’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Barclays’s Portfolio XPH Stock Details XPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.8K Buy
+344
New +$20.2K ﹤0.01% 4560
2025
Q3 		– Sell
-1,491
Closed -$60.5K – 5762
2025
Q2 		$60.5K Buy
+1,491
New +$59.9K ﹤0.01% 4678
2024
Q2 		– Sell
-100
Closed -$4.31K – 5367
2024
Q1 		$4.31K Hold
100
– – ﹤0.01% 4877
2023
Q4 		$4.16K Sell
100
-100
-50% -$3.79K ﹤0.01% 5041
2023
Q3 		$7.95K Buy
200
+100
+100% +$4.23K ﹤0.01% 4337
2023
Q2 		$4.1K Hold
100
– – ﹤0.01% 4290
2023
Q1 		$4.1K Hold
100
– – ﹤0.01% 4851
2022
Q4 		$4.09K Hold
100
– – ﹤0.01% 5022
2022
Q3 		$4K Hold
100
– – ﹤0.01% 4547
2022
Q2 		$4K Hold
100
– – ﹤0.01% 4823
2022
Q1 		$5K Hold
100
– – ﹤0.01% 4703
2021
Q4 		$5K Sell
100
-110
-52% -$5.21K ﹤0.01% 4026
2021
Q3 		$10K Sell
210
-734
-78% -$36.5K ﹤0.01% 4523
2021
Q2 		$49K Buy
944
+844
+844% +$42.4K ﹤0.01% 4142
2021
Q1 		$5K Hold
100
– – ﹤0.01% 4489
2020
Q4 		$5K Hold
100
– – ﹤0.01% 4783
2020
Q3 		$4K Hold
100
– – ﹤0.01% 5093
2020
Q2 		$4K Hold
100
– – ﹤0.01% 5411
2020
Q1 		$4K Sell
100
-47,300
-100% -$2.02M ﹤0.01% 5972
2019
Q4 		$2.17M Hold
47,400
– – ﹤0.01% 2914
2019
Q3 		$1.69M Hold
47,400
– – ﹤0.01% 3080
2019
Q2 		$1.89M Sell
47,400
-150,000
-76% -$5.9M ﹤0.01% 2989
2019
Q1 		$8.21M Buy
197,400
+150,000
+316% +$6.1M 0.01% 1350
2018
Q4 		$1.74M Buy
+47,400
New +$2.02M ﹤0.01% 2551
2017
Q2 		– Sell
-560
Closed -$23K – 6978
2017
Q1 		$23K Sell
560
-200,000
-100% -$8.15M ﹤0.01% 5749
2016
Q4 		$7.84M Hold
200,560
– – 0.01% 1077
2016
Q3 		$8.86M Hold
200,560
– – 0.01% 936
2016
Q2 		$8.38M Sell
200,560
-449,440
-69% -$19M 0.01% 948
2016
Q1 		$26M Buy
+650,000
New +$27.5M 0.04% 398

Other funds holding XPH

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
KWM
Kingsview Wealth Management Grants Pass, Oregon $8.25B AUM 24.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
Envestnet Portfolio Solutions
Envestnet Portfolio Solutions Chicago, Illinois $20.9B AUM 19.34% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
EP
Evelyn Partners London $46.9B AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Barclays's XPH Position: Q2 2026 in Review

Barclays opened a new position in State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q2 2026: 344 shares worth $22.8K. The stake represents ﹤0.01% of the portfolio and ranks #4560 among its holdings. This is a return to the name: Barclays previously reported a position in XPH as recently as Q2 2025.

Barclays first reported a position in XPH in Q1 2016 and has held it in 29 quarters since. The position peaked at $26M in Q1 2016. 93 funds tracked by Wall St. Rank hold XPH as of Q2 2026.

  • Barclays held 344 shares of State Street SPDR S&P Pharmaceuticals ETF worth $22.8K as of Q2 2026.
  • State Street SPDR S&P Pharmaceuticals ETF was a new Barclays position in Q2 2026.
  • State Street SPDR S&P Pharmaceuticals ETF made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4560 holding.
  • Barclays first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q1 2016 and has held it in 29 quarters since.
  • Barclays's State Street SPDR S&P Pharmaceuticals ETF position peaked at $26M in Q1 2016.
  • 93 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.